{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T17:59:47Z","timestamp":1787162387257,"version":"build-2736575974"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2023,6,24]],"date-time":"2023-06-24T00:00:00Z","timestamp":1687564800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,6,24]],"date-time":"2023-06-24T00:00:00Z","timestamp":1687564800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1007\/s00280-023-04551-6","type":"journal-article","created":{"date-parts":[[2023,6,24]],"date-time":"2023-06-24T07:39:02Z","timestamp":1687592342000},"page":"229-233","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Infections occurring following IL6 blockade for the management of cytokine release syndrome in onco-hematology patients"],"prefix":"10.1007","volume":"92","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7787-6911","authenticated-orcid":false,"given":"M.","family":"Valery","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Saleh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Ecea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. M.","family":"Michot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Ribrag","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Fizazi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Hollebecque","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Lecesne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Ponce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Loriot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Champiat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Baldini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Sarkozy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Castilla-Llorente","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,6,24]]},"reference":[{"key":"4551_CR1","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1016\/j.immuni.2019.03.026","volume":"50","author":"S Kang","year":"2019","unstructured":"Kang S, Tanaka T, Narazaki M, Kishimoto T (2019) Targeting interleukin-6 signaling in clinic. Immunity 50:1007\u20131023. https:\/\/doi.org\/10.1016\/j.immuni.2019.03.026","journal-title":"Immunity"},{"key":"4551_CR2","unstructured":"Drug Approval Package: ACTEMRA (tocilizumab). https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2017\/125276Orig1s114TOC.cfm. Accessed 16 Jan 2022"},{"key":"4551_CR3","unstructured":"SYLVANT (siltuximab). https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2014\/125496Orig1s000TOC.cfm. Accessed 16 Jan 2022"},{"key":"4551_CR4","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.jmii.2017.04.002","volume":"52","author":"C-T Lin","year":"2019","unstructured":"Lin C-T, Huang W-N, Hsieh C-W et al (2019) Safety and effectiveness of tocilizumab in treating patients with rheumatoid arthritis\u2014a three-year study in Taiwan. J Microbiol Immunol Infect 52:141\u2013150. https:\/\/doi.org\/10.1016\/j.jmii.2017.04.002","journal-title":"J Microbiol Immunol Infect"},{"key":"4551_CR5","doi-asserted-by":"publisher","first-page":"R141","DOI":"10.1186\/ar3455","volume":"13","author":"MH Schiff","year":"2011","unstructured":"Schiff MH, Kremer JM, Jahreis A et al (2011) Integrated safety in tocilizumab clinical trials. Arthritis Res Ther 13:R141. https:\/\/doi.org\/10.1186\/ar3455","journal-title":"Arthritis Res Ther"},{"key":"4551_CR6","doi-asserted-by":"publisher","DOI":"10.1126\/science.abb8925","author":"JB Moore","year":"2020","unstructured":"Moore JB, June CH (2020) Cytokine release syndrome in severe COVID-19. Science. https:\/\/doi.org\/10.1126\/science.abb8925","journal-title":"Science"},{"key":"4551_CR7","doi-asserted-by":"publisher","unstructured":"Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19|NEJM. https:\/\/doi.org\/10.1056\/NEJMoa2100433. Accessed 8 May 2022","DOI":"10.1056\/NEJMoa2100433"},{"key":"4551_CR8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2028700","author":"IO Rosas","year":"2021","unstructured":"Rosas IO, Br\u00e4u N, Waters M et al (2021) Tocilizumab in hospitalized patients with severe Covid-19 pneumonia. N Engl J Med. https:\/\/doi.org\/10.1056\/NEJMoa2028700","journal-title":"N Engl J Med"},{"key":"4551_CR9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2030340","author":"C Salama","year":"2020","unstructured":"Salama C, Han J, Yau L et al (2020) Tocilizumab in patients hospitalized with Covid-19 pneumonia. N Engl J Med. https:\/\/doi.org\/10.1056\/NEJMoa2030340","journal-title":"N Engl J Med"},{"key":"4551_CR10","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.26429","author":"NN Pettit","year":"2020","unstructured":"Pettit NN, Nguyen CT, Mutlu GM et al (2020) Late onset infectious complications and safety of tocilizumab in the management of COVID-19. J Med Virol. https:\/\/doi.org\/10.1002\/jmv.26429","journal-title":"J Med Virol"},{"key":"4551_CR11","doi-asserted-by":"publisher","DOI":"10.1101\/2020.05.15.20103531","author":"LM Kimmig","year":"2020","unstructured":"Kimmig LM, Wu D, Gold M et al (2020) IL6 inhibition in critically ill COVID-19 patients is associated with increased secondary infections. medRxiv. https:\/\/doi.org\/10.1101\/2020.05.15.20103531","journal-title":"medRxiv"},{"key":"4551_CR12","doi-asserted-by":"publisher","first-page":"67","DOI":"10.4103\/jgid.jgid_358_20","volume":"13","author":"JL Moore","year":"2021","unstructured":"Moore JL, Stroever SJ, Rondain PE, Scatena RN (2021) Incidence of secondary bacterial infections following utilization of tocilizumab for the treatment of COVID-19\u2014a matched retrospective cohort study. J Glob Infect Dis 13:67\u201371. https:\/\/doi.org\/10.4103\/jgid.jgid_358_20","journal-title":"J Glob Infect Dis"},{"key":"4551_CR13","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1182\/blood.2020006216","volume":"136","author":"MJ Frigault","year":"2020","unstructured":"Frigault MJ, Nikiforow S, Mansour MK et al (2020) Tocilizumab not associated with increased infection risk after CAR T-cell therapy: implications for COVID-19? Blood 136:137\u2013139. https:\/\/doi.org\/10.1182\/blood.2020006216","journal-title":"Blood"},{"key":"4551_CR14","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","volume":"25","author":"DW Lee","year":"2019","unstructured":"Lee DW, Santomasso BD, Locke FL et al (2019) ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol Blood Marrow Transplant 25:625\u2013638. https:\/\/doi.org\/10.1016\/j.bbmt.2018.12.758","journal-title":"Biol Blood Marrow Transplant"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-023-04551-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00280-023-04551-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-023-04551-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,22]],"date-time":"2023-07-22T06:02:16Z","timestamp":1690005736000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00280-023-04551-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,24]]},"references-count":14,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["4551"],"URL":"https:\/\/doi.org\/10.1007\/s00280-023-04551-6","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,24]]},"assertion":[{"value":"18 April 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 June 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 June 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"On behalf of all authors, the corresponding author states that there is no conflict of interest, related to the submitted work.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}